Anixa Biosciences Inc
anixa.comWhat Do They Do?
Develops cancer therapies and vaccines for ovarian and breast cancers, aiming to license them to pharmaceutical companies.
10-K for FY2025, filed Jan 12, 2026Anixa Biosciences, Inc. is a biotechnology company developing therapies and vaccines that are focused on critical unmet needs in oncology.…View ↗
Over the past several years, our revenue was derived from technology licensing and the sale of patented technologies, including revenue…View ↗
We have not generated any revenue to date from our therapeutics or vaccine programs. In addition, while we pursue our therapeutics and…View ↗
How Do They Make Money?
Companies paid one-time fees for rights to patented technology within 30 days of signing; Anixa hopes to earn future income by licensing its cancer therapies and vaccines to large pharmaceutical companies.
10-K for FY2025, filed Jan 12, 2026
$210K
-
10-K for FY2023, filed Jan 16, 2024
$210K ↗
Who Are Their Customers?
Past revenue came from companies that licensed patented technologies, including through litigation settlements; Anixa hopes to license cancer therapies and vaccines to large pharmaceutical companies.
10-K for FY2025, filed Jan 12, 2026We did not have any revenue in fiscal years 2025 and 2024. Over the past several years, our revenue, if any, was derived from technology…View ↗
We have not generated any revenue to date from our therapeutics or vaccine programs. In addition, while we pursue our therapeutics and…View ↗
Over the past several years, our revenue was derived from technology licensing and the sale of patented technologies, including revenue…View ↗
Do Revenues Turn Into Profits?
No. It lost $9.8M in FY2023.
How Are They Changing?
- Net income
-
Sources
10-Q for Q3 FY2026, filed Sep 9, 2026
−$2.6MView ↗
- ▲ +15% (Loss)
- vs −$2.3M in Q3 FY2025
Shrinking. Revenue fell 16% in 4 years, from $250K in FY2019 to $210K in FY2023, about 4% a year.
Cancer vaccine research expands
The older report described vaccines for breast and ovarian cancer; the latest report adds discovery work on vaccines for lung, colon and prostate cancers.
10-K for FY2022, filed Jan 4, 2023 10-K for FY2025, filed Jan 12, 2026We licensed certain technology from Cleveland Clinic to develop vaccines for the treatment or prevention of TNBC and other breast cancers…View ↗
In May 2024, based on the positive clinical results to date in the development of our breast cancer vaccine, we entered into a Joint…View ↗
Focus shifts to cancer
The older report included antiviral drug development, while the latest report describes its therapy and vaccine programs as focused on cancer.
10-K for FY2022, filed Jan 4, 2023 10-K for FY2025, filed Jan 12, 2026Anixa Biosciences, Inc. is a biotechnology company developing therapies and vaccines that are focused on critical unmet needs in oncology.…View ↗
Loading...
